Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Phase 3 Myasthenia Gravis Trials

15 Phase 3 trials for Myasthenia Gravis. Phase 3 trials are the final stage of testing before a treatment can be submitted for FDA approval.

What is a Phase 3 trial?

Phase 3 clinical trials study a treatment in large groups (hundreds to thousands of people) to confirm its effectiveness, monitor side effects, and compare it to standard treatments. These trials are the last major step before the FDA considers approving a new treatment.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
RECRUITINGPhase 3NCT06463587

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized...

The purpose of this clinical study is to determine the efficacy and safety of a new oral cladribine formulation in participants with Generalized Myasthenia Gravis (gMG) in...

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyEnrolling: 26420 locations
RECRUITINGPhase 3NCT06765161

Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

This study is an open label, single center, prospective, 26 weeks study with descriptive analysis where IVIG is replaced by efgartigimod therapy. MG-ADL and MGQOL evaluations will...

Sponsor: Clinique Neuro-OutaouaisEnrolling: 301 location
RECRUITINGPhase 3NCT06456580

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of generalized myasthenia gravis.

Sponsor: Vor BiopharmaEnrolling: 18020 locations
RECRUITINGPhase 3NCT06342544

Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter...

Myasthenia is an autoimmune disease causing dysfunction of the neuromuscular junction, resulting in fluctuating and variable muscle weakness. In the initial phase of the disease,...

Sponsor: Fondation Ophtalmologique Adolphe de RothschildEnrolling: 12811 locations
RECRUITINGPhase 3NCT06517758

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants...

The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG...

Sponsor: Novartis PharmaceuticalsEnrolling: 14620 locations
RECRUITINGPhase 3NCT06799247

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor...

Sponsor: Cartesian TherapeuticsEnrolling: 10020 locations
RECRUITINGPhase 3NCT07249632

A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG)

This is a Phase III, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Telitacicept for the treatment of Ocular...

Sponsor: RemeGen Co., Ltd.Enrolling: 1201 location
RECRUITINGPhase 3NCT06607627

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.

Sponsor: Alexion Pharmaceuticals, Inc.Enrolling: 1213 locations
RECRUITINGPhase 3NCT06587867

Seronegative Myasthenia Gravis - Efgartigimod IV

This is to study the efficacy, safety and tolerability of efgartigimod in patients with seronegative generalized myasthenia gravis. This is an open label study. There will be 30...

Sponsor: University Health Network, TorontoEnrolling: 301 location
RECRUITINGPhase 3NCT07215949

Zilucoplan for Severe gMG Exacerbations

This is an open-label, multicenter, interventional phase 3b study in participants with AChR+ gMG and severe exacerbation that require hospitalization. Patients will receive...

Sponsor: Miriam FreimerEnrolling: 151 location
RECRUITINGPhase 3NCT07217587

Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis

The purpose of this study is to assess how well nipocalimab works when compared to efgartigimod in participants with generalized myasthenia gravis (a condition in which body's...

Sponsor: Janssen Research & Development, LLCEnrolling: 1157 locations
RECRUITINGPhase 3NCT07039916

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

The purpose of the study is to assess the efficacy, safety and tolerability of IMVT-1402 in adult participants with mild to severe generalized myasthenia gravis.

Sponsor: Immunovant Sciences GmbHEnrolling: 23120 locations
RECRUITINGPhase 3NCT06744920

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With...

A study to evaluate the efficacy, safety and tolerability of Remibrutinib versus placebo in adult patients with Generalized Myasthenia Gravis who are on stable, standard-of-care...

Sponsor: Novartis PharmaceuticalsEnrolling: 18020 locations
RECRUITINGPhase 3NCT04951622

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the...

Sponsor: Janssen Research & Development, LLCEnrolling: 19920 locations
RECRUITINGPhase 3NCT05868837

Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)

The primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 401 location